Glenmark Pharmaceuticals Approves Policy Amendments and Designates Key Officials for Material Disclosures

Glenmark Pharmaceuticals Approves Policy Amendments and Designates Key Officials for Material Disclosures

Glenmark Pharmaceuticals Approves Policy Amendments and Designates Key Officials for Material Disclosures​

Glenmark Pharmaceuticals Limited announced that its Board of Directors meeting on July 31, 2026, approved amendments to the Company's Policy on Determination of Materiality for Disclosures. This action relates to defining the process and personnel responsible for assessing and communicating material events to the stock exchanges.

The board decision solidified the framework for managing and disclosing significant corporate information under regulatory guidelines. The Board meeting confirmed the officials authorized by Glenmark Pharmaceuticals Limited who are designated to determine the materiality of an event or information and handle disclosures required under relevant listing regulations.

The designated officials and their respective roles within the organization are as follows:

NameDesignation
Mr. Glenn SaldanhaChairman & Managing Director
Mrs. Cherylann PintoExecutive Director - Corporate Services
Mr. Anurag MantriExecutive Director & Global Chief Financial Officer
Ms. Rashmi KhandelwalCompany Secretary & Compliance Officer

GLENMARK Stock Price Movement​

Today, Glenmark's shares gained robustly, settling at ₹2233.9 after rising 2.73%. Investors watched as the stock traded within a strong intraday band, ranging from a low of ₹2207 to a high of ₹2256.7.
 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.

Last edited by a moderator:
Back
Top